Giselle Mosnaim, MD, MS 

Key Takeaways and Considerations for the Use of BTK Inhibitors in CSU Treatment

Video content above is prompted by the following:

What are some key takeaways on the potential use of BTK inhibitors in the treatment of CSU that you’d like to share with clinicians managing this condition?

Videos

Panelists discuss how Bruton tyrosine kinase (BTK) inhibitors represent a promising new therapeutic class for chronic spontaneous urticaria (CSU) by offering rapid symptom control through targeted inhibition of both mast cell and B cell pathways, with newer agents like remibrutinib showing high selectivity, favorable safety, and robust efficacy in clinical trials that could position them as an important oral therapy option between antihistamines and biologics.

Additional Data Needs for BTK Inhibitors in CSU

What additional data, if any, is needed surrounding BTK inhibitors and CSU?

Panelists discuss how future research should focus on identifying biomarkers for patient selection, understanding long-term safety profiles, exploring combination therapy approaches, and determining optimal treatment duration with Bruton tyrosine kinase (BTK) inhibitors in chronic spontaneous urticaria (CSU).

Evolving Paradigm for CSU Treatment

If approved, how would BTK inhibitors change the treatment spectrum for patients with CSU?

Panelists discuss how Bruton tyrosine kinase (BTK) inhibitors could transform chronic spontaneous urticaria (CSU) treatment by offering a targeted oral therapy option that works rapidly across both autoallergic and autoimmune subtypes, potentially providing an effective alternative before escalating to biologics or immunosuppressants.

How BTK Inhibitors Might Address Unmet Treatment Needs in CSU

How do data from these trials compare to results you see in practice with other, non-BTK options for CSU management?

Panelists discuss how Bruton tyrosine kinase (BTK) inhibitors appear to offer faster symptom relief and higher complete response rates compared with current chronic spontaneous urticaria (CSU) treatments like antihistamines and omalizumab while potentially requiring less frequent dosing and showing favorable safety profiles.

Giselle Mosnaim, MD, MS

Articles